The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Apr 2016 07:00

RNS Number : 2811U
Scancell Holdings Plc
06 April 2016
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Scancell Holdings plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Calculus Capital Limited

4. Full name of shareholder(s)  (if different from 3.):iv

Reyker Nominees/Investec Wealth and Investment

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

5 April 2016

6. Date on which issuer notified:

5 April 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

16%, 17%, 18%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

ISIN: GB00B63D3314

35,085,706

35,085,706

49,203,353

49,203,353

18.8%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

49,203,353

18.8%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

N/A

14. Contact name:

Calculus Capital Limited

15. Contact telephone number:

0207 493 4940

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFLTSEIEIIR
Date   Source Headline
18th Apr 201811:05 amRNSSecond Price Monitoring Extn
18th Apr 201811:00 amRNSPrice Monitoring Extension
18th Apr 20187:00 amRNSProposed Placing, Subscription and Open Offer
18th Apr 20187:00 amRNSTechnology acquired from University of Nottingham
3rd Apr 20187:00 amRNSManufacturing agreement with The PolyPeptide Group
16th Feb 201811:30 amRNSScancell to present at the Calculus Investor Forum
15th Feb 20187:15 amRNSHardman Res. - Validating multiple opportunities
15th Feb 20187:00 amRNSCollaboration agreement with ISA Pharmaceuticals
12th Feb 20187:00 amRNSPublication highlights potential of SCIB1 therapy
9th Feb 20187:00 amRNSEuropean patent application allowed for grant
8th Feb 20187:00 amRNSScancell member of team shortlisted for CRUK award
1st Feb 20187:00 amRNSDirector/PDMR Shareholding
30th Jan 20187:00 amRNSHalf-year Report
9th Jan 20187:00 amRNSScancell to collaborate with BioNTech
14th Dec 20177:00 amRNSScancell and CRUK to advance cancer immunotherapy
11th Oct 20179:44 amRNSResult of AGM
10th Oct 20177:00 amRNSDirectorate Change
14th Sep 20177:00 amRNSNotice of AGM
13th Sep 20177:00 amRNSFinal Results
11th Sep 20177:00 amRNSPresents Moditope Data at Immunotherapy Conference
29th Aug 20177:00 amRNSOncimmune and Scancell Present Autoantibodies Data
11th Jul 20177:00 amRNSContinued Progress on SCIB1
26th Jun 20177:00 amRNSDNA ImmunoBody Patent Granted in Europe
22nd May 201712:59 pmRNSHolding(s) in Company
19th May 20172:47 pmRNSHolding(s) in Company
19th May 20177:00 amRNSHolding(s) in Company
11th May 201712:09 pmRNSResults of Placing
11th May 20177:00 amRNSProposed Placing to Raise up to £5.0 million
13th Apr 201712:39 pmRNSChange of Registered Office
20th Mar 20177:00 amRNSImmuno-Oncology Summit Europe 2017
13th Mar 20177:15 amRNSHardman Research: SCIB development update
1st Mar 20177:00 amRNSHolding(s) in Company
31st Jan 20177:00 amRNSInterim Results
30th Jan 20177:00 amRNSPartnership to Advance Lung Cancer Clinical Trials
3rd Jan 201711:33 amRNSResearch Update - Amendment
3rd Jan 20177:00 amRNSResearch Update
14th Nov 20167:00 amRNSWorld Immunotherapy Congress and Biotech and Money
18th Oct 20165:42 pmRNSResults of AGM
10th Oct 20167:00 amRNSPreparing SCIB2 for clinical study in lung cancer
26th Sep 20167:15 amRNSHardman Report: New frontiers in T-cell activation
23rd Sep 20165:24 pmRNSNotice of AGM - Amendment
23rd Sep 20163:28 pmRNSNotice of AGM
16th Sep 20167:00 amRNSFinal Results
7th Sep 20167:00 amRNSNewsMakers in the Biotech Industry Conference
22nd Aug 20167:00 amRNSAppointment of Non-Executive Director
21st Jul 20167:00 amRNSEurogentec manufacturing agreement
20th Jul 20167:00 amRNSExtension to Ichor Commercial Option
13th Jul 20167:00 amRNSPeer-reviewed publication on Moditope® platform
6th Jul 20167:00 amRNSSCIB1 compelling survival data in melanoma
29th Jun 20164:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.